#United States #Bridgewater #Onkos Surgical #NanoCept #Orthopaedic Implants

Onkos Surgical Opens NanoCept Innovation Center

On December 9, 2025, Onkos Surgical marked a significant milestone by inaugurating the NanoCept Innovation Center in Bridgewater Township, New Jersey. This new facility represents a pivotal advancement in the company's efforts to combat bacterial contamination in orthopaedic procedures. The NanoCept technology, recognized as the first commercially available antibacterial coating for orthopaedic implants in the U.S., will now be developed and manufactured in-house, streamlining the innovation process.

The new center spans 4,600 square feet and is equipped to support Onkos Surgical's flagship product – the NanoCept® Antibacterial Technology. This initiative not only enhances the firm's production capacity but also aims to meet the growing demands from hospitals and surgeons who seek solutions to mitigate intraoperative bacterial risks. Patrick Treacy, CEO and founder of Onkos Surgical, expressed pride in this achievement, stating, "This investment will allow us to get this groundbreaking technology into the hands of more surgeons, faster, and it positions us to help more patients facing complex orthopaedic conditions."

Renowned orthopaedic oncologist, Dr. Steven Gitelis, who serves as the Chief Medical Officer of Onkos, also voiced his enthusiasm for the company's commitment to enhancing patient care. He stated, "This technology serves as a powerful tool for surgeons, significantly addressing the critical issue of bacteria in operating rooms."

Located within the New Jersey Center of Excellence Campus, the NanoCept Innovation Center will employ a diverse team of chemists, engineers, and technicians dedicated to driving the continuous development of revolutionary medical solutions. This move underscores Onkos Surgical's long-standing dedication to both innovation and the New Jersey region, where its primary headquarters in Parsippany is situated.

The ribbon-cutting ceremony was attended by various dignitaries, including Congressman Tom Kean Jr. He remarked, "The opening of the NanoCept Innovation Center exemplifies the cutting-edge innovation that defines New Jersey's 7th Congressional District. Advancements like those being pursued by Onkos Surgical have the potential to drive meaningful progress in patient care and expand possibilities in modern medicine."

With the establishment of this state-of-the-art facility, Onkos aims to ensure that more surgeons can access the NanoCept technology, making a lasting impact on patient safety and outcomes in orthopaedic procedures. By offering a proactive approach to minimize the risk of infection during surgery, this technology could transform how implants are utilized in the medical field.

Onkos Surgical is recognized for its innovative solutions tailored for complex orthopaedic challenges. Their commitment to improve patient outcomes through personalized approaches and cutting-edge technologies, such as antibacterial implant coatings and 3D anatomic modeling, positions them as leaders in the field. With over 350 top academic medical institutions leveraging Onkos solutions for complex orthopaedic cases, the future looks bright for advancements driven by the new NanoCept Innovation Center.

Prospective patients and healthcare providers will greatly benefit from this facility, which not only showcases Onkos' dedication to innovation but also marks a significant leap forward in improving surgical protocols and patient safety. As Onkos Surgical continues to lead in this essential area of healthcare, their new innovation center stands as a testament to their commitment to excellence and progress in orthopaedic solutions.